cas 1207351-15-2|| where to buy 5-ethynyl-1H-pyrazolo[3,4-b]pyridine

Nom du produit:5-ethynyl-1H-pyrazolo[3,4-b]pyridine

IUPAC Name:5-ethynyl-1H-pyrazolo[3,4-b]pyridine

Unité d'emballage	Stock disponible	Prix($)
CM111790-100mg	in stock	ľƈ
CM111790-250mg	in stock	ŌǸƈ
CM111790-1g	in stock	ǪľŌ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1207351-15-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1207351-15-2; Formule moléculaire:C8H5N3; Point de fusion:-; Code SMILES:C#CC1=CN=C(NN=C2)C2=C1; Densité:

: Numéro de catalogue:CM111790; Poids moléculaire:143.15; Point d'ébullition:; N° Mdl:MFCD22187975; Stockage:

: Pyrazolopyridines; Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.

: Olverembatinib; Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.